Telix Pharmaceuticals Limited
ASX: TLX
Illuccix-fueled surge and RLS expansion drive growth, with Gozellix launch and rising R&D priming further U.S. uptake.
Telix posted strong H1 FY2025 results, with revenue surging 69.0% YoY to $615.34 million, underpinned by rapid Illuc
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
